Delcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018
13. September 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its...
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology
04. September 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces Extension of Rights Offering Period to September 26, 2018
28. August 2018 08:33 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Delcath Announces Acceptance of Abstract for Poster Presentation at CIRSE 2018
27. August 2018 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification
23. August 2018 11:14 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces Pending Expiration to Rights Offering Subscription Period
22. August 2018 09:41 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its...
First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma
21. August 2018 08:52 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial
20. August 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Issues Letter to Stockholders
17. August 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH) (“Delcath” or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic...
Delcath Announces Second Quarter Fiscal 2018 Financial Results
15. August 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces...